BioXcel Therapeutics

BioXcel Therapeutics is a company focused on developing transformative medicines in the fields of neuroscience and immuno-oncology by utilizing artificial intelligence (AI) techniques. The company employs a unique AI platform, NovareAI, to reduce therapeutic development costs, potentially accelerate timelines, and increase the possibility of success. BioXcel Therapeutics has a wholly owned, clinical-stage subsidiary named OnkosXcel Therapeutics, which concentrates on developing medicines for immuno-oncology. OnkosXcel Therapeutics was formed in 2022 to advance new treatment options for patients with hard-to-treat tumors. The company’s AI-based approach led to the rapid advancement of its first commercial product, IGALMI™ (dexmedetomidine) sublingual film, from first-in-human clinical trials to FDA approval and launch in less than four years. IGALMI™ is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Another key product, BXCL501, is being evaluated as a potential treatment for agitation associated with multiple psychiatric and neurological disorders. BXCL501 has received Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia. Additionally, BXCL701 is an investigational oral innate immune activator being developed as a potential therapy for aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. BXCL701 has received Orphan Drug Designation from the FDA in four indications: acute myelogenous leukemia, pancreatic cancer, stage IIb to IV melanoma, and soft tissue sarcoma, and has also received Fast Track designation for small cell neuroendocrine phenotype (SCNC). The company is headquartered at 555 Long Wharf Drive, 12th Floor, New Haven, CT 06511, United States. BioXcel Therapeutics’ proprietary drug development approach aims to leverage existing approved drugs and/or clinically evaluated product candidates to discover and develop new indications.